Ocumension Therapeutics (HK:1477)
:1477
Want to see HK:1477 full AI Analyst Report?
Top Page
Ocumension Therapeutics
(1477)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$7.50
▼(-0.66% Downside)
Action:ReiteratedDate:05/02/26
The score is primarily supported by improving financial performance (strong revenue growth and a low-leverage balance sheet), but it is held back by persistent negative cash flow and losses. Technically, the stock shows mixed-to-weak momentum, and valuation is constrained by the negative P/E and lack of dividend.
Positive Factors
Conservative Balance Sheet
Very low leverage and a sizable equity base provide financial flexibility for R&D, regulatory timelines and commercialization. A conservatively levered balance sheet reduces refinancing risk, supports strategic investments, and cushions the company while it scales its ophthalmology portfolio over several years.
Negative Factors
Persistent Negative Operating Cash Flow
Consistent negative operating cash flow forces reliance on external funding and increases execution risk. Over months to a few years, ongoing cash deficits can constrain development cadence, require dilutive capital raises, and limit the firm's ability to self-fund launches or geographic expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and a sizable equity base provide financial flexibility for R&D, regulatory timelines and commercialization. A conservatively levered balance sheet reduces refinancing risk, supports strategic investments, and cushions the company while it scales its ophthalmology portfolio over several years.
Read all positive factors
Ocumension Therapeutics (1477) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.03B
Dividend YieldN/A
Average Volume (3M)3.41M
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue Growth93.26%
EPS Growth49.33%
CountryHK
Employees489
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)1.43
Price to Sales (P/S)6.74
P/FCF Ratio-14.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.16Price Target Upside34.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$1.10B
Ocumension Therapeutics Business Overview & Revenue Model
Company Description
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers ...
How the Company Makes Money
null...
Ocumension Therapeutics Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 543.72M | 783.53M | 417.31M | 246.37M | 158.96M | 56.15M |
| Gross Profit | 231.51M | 343.08M | 225.06M | 144.37M | 102.92M | 36.94M |
| EBITDA | -198.88M | -147.56M | -188.03M | -320.62M | -359.98M | -249.81M |
| Net Income | -249.25M | -154.71M | -268.27M | -379.79M | -402.64M | -259.99M |
Balance Sheet | ||||||
| Total Assets | 3.90B | 4.09B | 3.97B | 3.27B | 3.04B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 578.27M | 402.63M | 769.21M | 1.05B | 1.29B | 1.77B |
| Total Debt | 83.22M | 187.62M | 25.78M | 137.98M | 29.58M | 11.21M |
| Total Liabilities | 243.82M | 410.38M | 200.19M | 351.03M | 295.04M | 222.88M |
| Stockholders Equity | 3.65B | 3.68B | 3.77B | 2.92B | 2.75B | 3.11B |
Cash Flow | ||||||
| Free Cash Flow | -195.07M | -358.65M | -408.97M | -539.79M | -510.66M | -861.66M |
| Operating Cash Flow | -160.92M | -105.29M | -178.83M | -177.93M | -200.66M | -196.85M |
| Investing Cash Flow | -174.67M | -361.46M | 275.91M | -259.78M | 229.15M | -1.35B |
| Financing Cash Flow | -69.99M | 118.04M | -213.79M | 108.66M | -9.22M | 668.85M |
Ocumension Therapeutics Technical Analysis
Positive
7.55
Price Trends
7.27
Positive
7.55
Positive
8.42
Negative
Market Momentum
0.30
Negative
62.68
Neutral
60.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1477, the sentiment is Positive. The current price of 7.55 is below the 20-day moving average (MA) of 7.65, above the 50-day MA of 7.27, and below the 200-day MA of 8.42, indicating a neutral trend. The MACD of 0.30 indicates Negative momentum. The RSI at 62.68 is Neutral, neither overbought nor oversold. The STOCH value of 60.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1477.
Ocumension Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$6.03B | -34.12 | -4.32% | ― | 93.26% | 49.33% | |
51 Neutral | HK$9.35B | 30.77 | 24.17% | ― | 154.21% | ― | |
50 Neutral | HK$14.67B | -15.44 | -64.19% | ― | -33.37% | -344.90% | |
47 Neutral | HK$1.59B | -7.14 | -12.64% | ― | -53.85% | 12.23% | |
41 Neutral | HK$6.92B | -41.82 | -5.07% | ― | -2.04% | -46.97% |
* Healthcare Sector Average
HK:1477
Ocumension Therapeutics
7.40
2.02
37.55%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.18
0.30
6.15%
HK:2616
CStone Pharmaceuticals
9.30
6.45
226.32%
HK:6622
Zhaoke Ophthalmology Ltd.
2.90
1.21
71.60%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.84
-3.16
-31.60%
HK:0775
CK Life Sciences International (Holdings), Inc.
0.72
-0.21
-22.58%
Ocumension Therapeutics Corporate Events
Ocumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-211
Mar 30, 2026
Ocumension Therapeutics has reported a key milestone in its ophthalmology pipeline, announcing that the first patient has been enrolled in a phase III clinical trial in China for OT-211, a 0.003% eye drop formulation of AR-15512, the first TRPM8 a...
Ocumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth
Mar 26, 2026
Ocumension Therapeutics reported a sharp acceleration in growth for 2025, with revenue surging 92.7% year on year to RMB804.4 million and a comprehensive gross margin of 44.9%, driven mainly by strong sales of ophthalmic products including Xalatan...
Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement
Mar 26, 2026
Ocumension Therapeutics announced that independent non-executive director Ting Yuk Anthony Wu will retire at the upcoming annual general meeting after more than five years of service, stepping down as chairman of the audit committee and as a membe...
Ocumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend
Mar 10, 2026
Ocumension Therapeutics has scheduled a board meeting for March 26, 2026, to review and approve the audited annual results for the year ended December 31, 2025. The board will also consider publishing these results and evaluating whether to recomm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.